PLACEBO CONTROLLED, DOUBLE-BLIND EVALUATION OF LEVAMISOLE IN THE REDUCTION OF THE FREQUENCY, DURATION AND SEVERITY OF ATTACKS IN CHILDREN SUFFERING FROM RECURRENT UPPER RESPIRATORY-TRACT INFECTIONS

In a double-blind placebo controlled study of levamisole in the treatment of children with recurrent upper respiratory tract infection (URI) eighty-six patients took part. Medication was given Once a week, in a single body-weight adjusted dose. The children treated with levamisole had a statistically significantly reduced incidence of episodes of infection which were less severe, less prolonged and required less antibiotics. No side-effects were reported.